Aquestive Therapeutics (AQST) Gross Profit (2017 - 2025)
Historic Gross Profit for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $8.3 million.
- Aquestive Therapeutics' Gross Profit fell 883.03% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.4 million, marking a year-over-year decrease of 17586.23%. This contributed to the annual value of -$16.9 million for FY2024, which is 15668.19% down from last year.
- Latest data reveals that Aquestive Therapeutics reported Gross Profit of $8.3 million as of Q3 2025, which was down 883.03% from $5.4 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Gross Profit ranged from a high of $15.6 million in Q2 2024 and a low of -$49.2 million during Q4 2024
- Moreover, its 5-year median value for Gross Profit was $6.8 million (2022), whereas its average is $3.9 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Gross Profit surged by 76956.95% in 2021, and later crashed by 73705.33% in 2024.
- Aquestive Therapeutics' Gross Profit (Quarter) stood at $7.7 million in 2021, then plummeted by 30.28% to $5.4 million in 2022, then soared by 43.65% to $7.7 million in 2023, then plummeted by 737.05% to -$49.2 million in 2024, then surged by 116.87% to $8.3 million in 2025.
- Its last three reported values are $8.3 million in Q3 2025, $5.4 million for Q2 2025, and $5.1 million during Q1 2025.